Declining ALS Patients Are Waiting On The FDA...

When new neighbors move into Gainesboro, Tennessee, a small town at the foothills of Appalachia, locals are confused. Who are these self-proclaimed pioneers? And what do they want with their little town?Locals soon discover the new arrivals are connected to something much larger: ...  Show more

For generations, women have struggled to access information about menopause and how best to treat its symptoms. Social media and the rise of telehealth have filled some of that gap, giving way to a $19 billion economy. But is the commercial menopause marketplace serving women or ...  Show more

ALS is a fatal neurological disease that kills motor neurons. Even though it was first described more than 150 years ago, there is no cure, and the few drugs available only dampen the symptoms or slow the progression by a few months. In recent years new drugs have emerged. How ...

ALS is a disease that destroys the nerve cells in the brain and spinal cord we need for voluntary movement. There is no cure, but now there is a newly approved medication that may slow down the disease and extend patients' lives. The drug, called Relyvrio, got its start with a co ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more